title: [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].
abstract: The review considers the chemical structure, pharmacodynamics and pharmacokinetics of telaprevir, a new direct-acting antiviral agent, used to treat patients with chronic hepatitis C (CHC). The given data on Phase II and III clinical trials enable the authors to state the high efficacy of the drug in patients infected with hepatitis C virus type 1. The paper also provides data on the resistance of telaprevir and its drug interaction and denotes the place of the drug in the current antiviral treatment of patients with CHC.
authors.forename: I G
authors.initials: IG
authors.lastname: Nikitin
authors.forename: L M
authors.initials: LM
authors.lastname: Gogova
authors.forename: I E
authors.initials: IE
authors.lastname: Baikova
authors.forename: V A
authors.initials: VA
authors.lastname: Kislyakov
authors.forename: V M
authors.initials: VM
authors.lastname: Volynkina
mesh_terms: D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D009842:Oligopeptides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir